The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

In my seven years as a beauty writer, oily skin has been one of the trickiest skin types to nail down. Despite what it might look like on the surface, too much oil can be the result of dehydrated ...

Read more here. Turning 50 is a major milestone for your skin. While your 30s and 40s may have been about preventative steps (such as protecting your skin from environmental aging and keeping the ...

Researchers Shed Light on How to Predict Which Skin Cancer Patients Are Most Likely to Respond to Immunotherapy Jan. 8, 2025 — An international team of UK and US scientists discovered that the ...

Oxidative Stress: Neuropathy, Excitability, and Neurodegeneration.

Research breakthroughs are giving patients with atopic dermatitis/eczema more ways to treat this condition. See what a treatment plan may include.